{"count":5,"index":{"built_at":"2026-07-28T06:01:45.413905+00:00","public_records":55311,"revision":"bda2189ed965b7bae9093199"},"query":{"area":null,"kind":null,"lang":null,"limit":10,"match_mode":"all_terms","q":"Evidence check: CYP2C19 in the context of gut health"},"results":[{"answer":"The role of CYP2C19 in gut health is indirect and not strongly established. CYP2C19 is a key drug-metabolizing enzyme that processes proton pump inhibitors (PPIs) like omeprazole and the antiplatelet drug clopidogrel. PPIs are commonly used for heartburn and gastric ulcers—conditions that can alter the gut microbiome. Poor metabolizers (carriers of *2 or *3 variants) have higher PPI exposure, which may increase the risk of small intestinal bacterial overgrowth (SIBO) and Clostridioides difficile infection. Additionally, CYP2C19 polymorphisms can influence the success of Helicobacter pylori eradication therapy. However, direct evidence linking CYP2C19 to gut health independent of medication is weak. Most data come from pharmacogenetic studies, not from population-based gut health research. Therefore, testing CYP2C19 in the context of gut health is only relevant if PPI or clopidogrel therapy is being considered. Without such medication, the predictive value is low. The provided context lacks specific information on CYP2C19 and gut health, so this answer is based on general pharmacogenetic knowledge.","area":"gesundheit","canonical_id":"gesundheit:canonical-bd6bee395f0eb2391c7ae898","id":"public-919c5a96d79239be17633be9","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Evidence check: CYP2C19 in the context of gut health","score":24.80301901,"snippet":"The role of CYP2C19 in gut health is indirect and not strongly established. CYP2C19 is a key drug-metabolizing enzyme that processes proton pump inhibitors (PPIs) like omeprazole and the antiplatelet drug clopidogrel. PPIs are commonly used for heartburn and gastric ulcers—conditions that can alter the gut microbiome. Poor metabolizers (carriers of *2 or *3 variants) have higher PPI exposure, which may increase the risk of small intestinal bacterial overgrowth (SIBO) and Clostridioides difficile infection. Additionally, CYP2C19 polymorphisms can influence the success of Helicobacter pylori eradication therapy. However, direct evidence linking CYP2C19 to gut health independent of medication i","sources":[],"title":"Evidence check: CYP2C19 in the context of gut health","url":"https://tikki.wiki/wissen/gesundheit/frage/public-919c5a96d79239be17633be9/evidence-check-cyp2c19-in-the-context-of-gut-health/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}},{"answer":"CYP2C19 is a drug-metabolizing enzyme that breaks down proton pump inhibitors (PPIs) like omeprazole. In the context of gut health, its relevance is indirect: long-term PPI use alters the gut microbiome (increases Enterococcus, reduces diversity) and raises risk for C. difficile infections and nutrient malabsorption (B12, magnesium, iron). Carriers of 'slow metabolizer' variants (e.g., *2/*3) have higher PPI exposure, potentially amplifying microbiome shifts. However, the single-gene effect is small; clinical utility for personalized gut health advice is unproven by RCTs. Evidence is mechanistic (pharmacokinetics) and based on association studies, not on tailored dietary or probiotic recommendations. Caveat: Without PPI use, CYP2C19 has little direct impact on gut health. A DNA test alone is not actionable.","area":"gesundheit","canonical_id":"gesundheit:canonical-6ba713cedd7a7027769f1851","id":"public-fa29adb25cc3e7c1d4d9b077","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Evidence check: CYP2C19 in the context of Darmgesundheit","score":24.35656188,"snippet":"CYP2C19 is a drug-metabolizing enzyme that breaks down proton pump inhibitors (PPIs) like omeprazole. In the context of gut health, its relevance is indirect: long-term PPI use alters the gut microbiome (increases Enterococcus, reduces diversity) and raises risk for C. difficile infections and nutrient malabsorption (B12, magnesium, iron). Carriers of 'slow metabolizer' variants (e.g., *2/*3) have higher PPI exposure, potentially amplifying microbiome shifts. However, the single-gene effect is small; clinical utility for personalized gut health advice is unproven by RCTs. Evidence is mechanistic (pharmacokinetics) and based on association studies, not on tailored dietary or probiotic recomme","sources":[],"title":"Evidence check: CYP2C19 in the context of Darmgesundheit","url":"https://tikki.wiki/wissen/gesundheit/frage/public-fa29adb25cc3e7c1d4d9b077/evidence-check-cyp2c19-in-the-context-of-darmgesundheit/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}},{"answer":"The query asks for an evidence check on a 'Menopause Check' in the context of gut health. None of the provided knowledge contexts describe or validate such a test. The entries cover DNA variants (AQP3, SOD2, FUT2, CYP2C19, LEP, MTHFR, PPARA), a diet-plan book, and a vitamin D test – none relate to menopause or gut microbiome. Generally, menopause alters hormone levels (e.g., estrogen decline), which can affect gut microbiota composition and diversity. However, a specific 'Menopause Check' for gut health lacks robust scientific validation. Consumer tests in this niche often rely on marketing rather than strong human evidence. Without direct context, the evidence rating is 'unclear'. Caution is warranted: no single test can reliably capture the complex interplay between hormones, microbiome, and menopausal symptoms. Clinical assessment and validated biomarkers (e.g., FSH, estradiol) remain the standard.","area":"gesundheit","canonical_id":"gesundheit:canonical-73d883e65715fdd01f155184","id":"public-cc2199f9b1071a4cd0d692fc","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Evidence check: Menopause Check in the context of gut health","score":22.84162923,"snippet":"The query asks for an evidence check on a 'Menopause Check' in the context of gut health. None of the provided knowledge contexts describe or validate such a test. The entries cover DNA variants (AQP3, SOD2, FUT2, CYP2C19, LEP, MTHFR, PPARA), a diet-plan book, and a vitamin D test – none relate to menopause or gut microbiome. Generally, menopause alters hormone levels (e.g., estrogen decline), which can affect gut microbiota composition and diversity. However, a specific 'Menopause Check' for gut health lacks robust scientific validation. Consumer tests in this niche often rely on marketing rather than strong human evidence. Without direct context, the evidence rating is 'unclear'. Caution i","sources":[],"title":"Evidence check: Menopause Check in the context of gut health","url":"https://tikki.wiki/wissen/gesundheit/frage/public-cc2199f9b1071a4cd0d692fc/evidence-check-menopause-check-in-the-context-of-gut-health/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}},{"answer":"The pharmacogenetics Medicheck analyzes genetic variants in drug-metabolizing enzymes (e.g., CYP450, TPMT). In the context of gut health, direct evidence is weak. While drugs like proton pump inhibitors (PPIs) or antibiotics can alter the gut microbiome, and their metabolism is partly genetically controlled (e.g., CYP2C19 for PPIs), the clinical relevance for individual gut health is unclear. Most studies are mechanistic or GWAS-based with small effect sizes. A PGx test may offer clues about drug tolerance but does not replace stool analysis or dietary advice. Consumers should be aware: its predictive power for specific gut issues is limited, and many claims are marketing-driven. A holistic approach (microbiome, nutrition, lifestyle) remains essential.","area":"gesundheit","canonical_id":"gesundheit:canonical-474ad14d4cfa86ca730c76b2","id":"public-c8b4301d1b9c55cdd663472f","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Evidence check: Pharmakogenetik Medicheck in the context of gut health","score":22.82213601,"snippet":"The pharmacogenetics Medicheck analyzes genetic variants in drug-metabolizing enzymes (e.g., CYP450, TPMT). In the context of gut health, direct evidence is weak. While drugs like proton pump inhibitors (PPIs) or antibiotics can alter the gut microbiome, and their metabolism is partly genetically controlled (e.g., CYP2C19 for PPIs), the clinical relevance for individual gut health is unclear. Most studies are mechanistic or GWAS-based with small effect sizes. A PGx test may offer clues about drug tolerance but does not replace stool analysis or dietary advice. Consumers should be aware: its predictive power for specific gut issues is limited, and many claims are marketing-driven. A holistic ","sources":[],"title":"Evidence check: Pharmakogenetik Medicheck in the context of gut health","url":"https://tikki.wiki/wissen/gesundheit/frage/public-c8b4301d1b9c55cdd663472f/evidence-check-pharmakogenetik-medicheck-in-the-context-of-gut-health/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}},{"answer":"A longevity DNA test in the context of gut health currently lacks robust scientific evidence. The markers tested by MyBody-X (e.g., CYP2C19, FUT2, TNF) have only indirect and very small effects on inflammatory pathways or the gut microbiome, and are not validated for predicting gut health or longevity. Microbiome tests are also not FDA-approved and show poor reproducibility. The evidence for direct links between these SNPs and gut health is weak, mostly based on association studies. A Mediterranean diet, however, is well-supported to improve both gut microbiota and longevity (PMC13164940). Bottom line: the test offers no clinically actionable insights for gut health and should not replace medical advice or dietary guidance.","area":"gesundheit","canonical_id":"gesundheit:canonical-c97b3d3b249dd8653f0cbd5a","id":"public-262c5615b2d14c651a53de4c","kind":"qa","language":"en","publication_status":"existing_native_answer_privacy_screened_sources_pending","question":"Evidence check: Longevity DNA Test in the context of Darmgesundheit","score":22.6522397,"snippet":"A longevity DNA test in the context of gut health currently lacks robust scientific evidence. The markers tested by MyBody-X (e.g., CYP2C19, FUT2, TNF) have only indirect and very small effects on inflammatory pathways or the gut microbiome, and are not validated for predicting gut health or longevity. Microbiome tests are also not FDA-approved and show poor reproducibility. The evidence for direct links between these SNPs and gut health is weak, mostly based on association studies. A Mediterranean diet, however, is well-supported to improve both gut microbiota and longevity (PMC13164940). Bottom line: the test offers no clinically actionable insights for gut health and should not replace me","sources":[],"title":"Evidence check: Longevity DNA Test in the context of Darmgesundheit","url":"https://tikki.wiki/wissen/gesundheit/frage/public-262c5615b2d14c651a53de4c/evidence-check-longevity-dna-test-in-the-context-of-darmgesundheit/","verification":{"claim_support_verified":false,"human_reviewed":false,"quote_exact_match":false,"source_identity_verified":false,"tier":"existing_native_answer_privacy_screened_sources_pending"}}],"schema_version":"tikki.search-response.v1"}